Announcements Trials

Browse Landscape

Phase

Phase 1/2 3 Phase 3 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

OTHER 57 INDUSTRY 23 OTHER_GOV 2 NIH 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 1 Amyloidosis 1

Interventions

Cisplatin 118 Radiotherapy 114 Cyclophosphamide 93 Paclitaxel 84 Gemcitabine 74 Carboplatin 67 Filgrastim 60 Doxorubicin 57 Vincristine 56 Etoposide 56 Docetaxel 56 Fluorouracil 51 Cytarabine 41 Prednisone 40 Methotrexate 40 Leucovorin 39 Dexamethasone 37 Capecitabine 36 Irinotecan 35 Rituximab 29 Oxaliplatin 28 Granulocyte Colony-Stimulating Factor 27 Cetuximab 26 Bevacizumab 26 durvalumab 24 Temozolomide 24 Radiotherapy, Intensity-Modulated 24 Peripheral Blood Stem Cell Transplantation 24 Magnetic Resonance Spectroscopy 24 Surgical Procedures, Operative 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × pomalidomide × Clear all

NCT05066607 2024-03-06

IsAMYP

Intergroupe Francophone du Myelome

Phase 2 Unknown

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡